Blistering Disorders in the Elderly: Differential Diagnosis and Management Challenges
Keywords:
Geriatric Dermatology, Autoimmune Blistering Diseases, Bullous Pemphigoid, Pemphigus VulgarisAbstract
Background: The aging integument is particularly susceptible to a spectrum of blistering disorders, which present significant diagnostic and therapeutic challenges in the growing geriatric population. These conditions range from benign, trauma-induced blisters to severe, chronic autoimmune blistering diseases (AIBDs) like bullous pemphigoid (BP) and pemphigus vulgaris (PV), which carry substantial morbidity and mortality.
Objectives: This review aims to provide a comprehensive analysis of blistering disorders in the elderly, focusing on their pathophysiology, clinical presentation, diagnostic workup, and the unique complexities of management in this vulnerable demographic.
Methods: A detailed review of the scientific literature was conducted, synthesizing information on the epidemiology, pathogenesis, and evidence-based management of common geriatric blistering diseases in 3 data bases [PubMed – Google scholar- Google]. The analysis covers the structural and immunological basis of blister formation, the critical role of histopathology and direct immunofluorescence in diagnosis, and the tiered approach to treatment.
Results: The pathophysiological basis of blistering disorders involves a disruption of dermo-epidermal cohesion, driven by autoimmune responses against structural proteins like BP180, BP230, and desmogleins, against a backdrop of age-related skin fragility. Bullous pemphigoid is the most prevalent AIBD in the elderly, characterized by tense bullae and a pruritic prodrome, while pemphigus vulgaris, though rarer, is more acute and potentially fatal, presenting with flaccid bullae and mucosal erosions. Accurate diagnosis relies on a combination of clinical features, histopathology to determine blister level, and direct immunofluorescence to identify antibody deposition patterns. Management is a delicate balance, employing potent topical corticosteroids for limited disease and systemic immunosuppressants (e.g., corticosteroids, mycophenolate mofetil, azathioprine) for widespread involvement. For refractory cases, biologic agents like rituximab and intravenous immunoglobulin offer effective alternatives. Treatment in the elderly is complicated by polypharmacy and a high risk of adverse effects from immunosuppression, necessitating a tailored, multidisciplinary approach.
Conclusion: Blistering disorders in the elderly represent a complex interplay of immunosenescence and cutaneous aging. A systematic diagnostic approach is crucial for differentiating between AIBDs and other blistering conditions. Management must be highly individualized, prioritizing disease control while mitigating the profound risks associated with immunosuppressive therapies, with the ultimate goal of preserving quality of life and functional independence in this susceptible population.
Downloads
References
Kolarsick PA, Kolarsick MA, Goodwin C. Anatomy and physiology of the skin. Journal of the Dermatology Nurses' Association. 2011 Jul 1;3(4):203-13
Farage MA, Miller KW, Elsner P, Maibach HI. Characteristics of the aging skin. Advances in wound care. 2013 Feb 1;2(1):5-10.
Baumann L. Skin ageing and its treatment. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland. 2007 Jan;211(2):241-51.
Schmidt E, Della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Dermatologic clinics. 2011 Jul 1;29(3):427-38.
Joly P, Litrowski N. Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis). Clinics in dermatology. 2011 Jul 1;29(4):432-6.
Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, Fine JD, Foster CS, Ghohestani R, Hashimoto T, Hoang-Xuan T. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Archives of dermatology. 2002 Mar 1;138(3):370-9.
Woodley DT, Briggaman RA, O'Keefe EJ, Inman AO, Queen LL, Gammon WR. Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. New England Journal of Medicine. 1984 Apr 19;310(16):1007-13.
Wallach D. Pyoderma gangrenosum. InNeutrophilic dermatoses 2018 May 3 (pp. 55-83). Cham: Springer International Publishing.
Strowd LC, Taylor SL, Jorizzo JL, Namazi MR. Therapeutic ladder for pemphigus vulgaris: emphasis on achieving complete remission. Journal of the American Academy of Dermatology. 2011 Mar 1;64(3):490-4.
Green KJ, Simpson CL. Desmosomes: new perspectives on a classic. Journal of Investigative Dermatology. 2007 Nov 1;127(11):2499-515.
Amagai M. Pemphigus Vulgaris and Its Active. Dermatologic Immunity. 2008 May 26;10:167-81.
Fine JD, Eady RA, Bauer EA, Bauer JW, Bruckner-Tuderman L, Heagerty A, Hintner H, Hovnanian A, Jonkman MF, Leigh I, McGrath JA. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. Journal of the American Academy of Dermatology. 2008 Jun 1;58(6):931-50.
Schmidt E, Zillikens D. Pemphigoid diseases. The Lancet. 2013 Jan 26;381(9863):320-32.
Liu Z, Giudice GJ, Swartz SJ, Fairley JA, Till GO, Troy JL, Diaz LA. The role of complement in experimental bullous pemphigoid. The Journal of clinical investigation. 1995 Apr 1;95(4):1539-44.
Waschke J. The desmosome and pemphigus. Histochemistry and cell biology. 2008 Jul;130(1):21-54.
Uitto J, Richard G. Progress in epidermolysis bullosa: from eponyms to molecular genetic classification. Clinics in dermatology. 2005 Jan 1;23(1):33-40.
Joly P, Baricault S, Sparsa A, Bernard P, Bédane C, Duvert-Lehembre S, Courville P, Bravard P, Rémond B, Doffoel-Hantz V, Bénichou J. Incidence and mortality of bullous pemphigoid in France. Journal of Investigative Dermatology. 2012 Aug 1;132(8):1998-2004.
Schmidt E, Della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Dermatologic clinics. 2011 Jul 1;29(3):427-38.
Cortés B, Marazza G, Naldi L, Combescure C, Borradori L, Autoimmune Bullous Disease Swiss Study Group. Mortality of bullous pemphigoid in Switzerland: a prospective study. British journal of dermatology. 2011 Aug 1;165(2):368-74.
Bystryn JC, Rudolph JL. Pemphigus. The Lancet. 2005 Jul 2;366(9479):61-73.
Woodley DT, Briggaman RA, O'Keefe EJ, Inman AO, Queen LL, Gammon WR. Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. New England Journal of Medicine. 1984 Apr 19;310(16):1007-13.
Gupta R, Woodley DT, Chen M. Epidermolysis bullosa acquisita. Clinics in dermatology. 2012 Jan 1;30(1):60-9.
Salmi TT. Dermatitis herpetiformis. Clinical and experimental dermatology. 2019 Oct 1;44(7):728-31.
Zone JJ, Taylor TB, Kadunce DP, Chorzelski TP, Schachner LA, Huff JC, Meyer LJ, Petersen MJ. IgA antibodies in chronic bullous disease of childhood react with a 97 kDa basement membrane zone protein. Journal of investigative dermatology. 1996 Jun 1;106(6):1277-80.
Amagai M. Pemphigus Vulgaris and Its Active. Dermatologic Immunity. 2008 May 26;10:167-81.
Stavropoulos PG, Soura E, Antoniou C. Drug‐induced pemphigoid: a review of the literature. Journal of the European Academy of Dermatology and Venereology. 2014 Sep;28(9):1133-40.
Gammon WR, Briggaman RA, Inman III AO, Queen LL, Wheeler CE. Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin. Journal of investigative dermatology. 1984 Feb 1;82(2):139-44.
Sitaru C, Dähnrich C, Probst C, Komorowski L, Blöcker I, Schmidt E, Schlumberger W, Rose C, Stöcker W, Zillikens D. Enzyme‐linked immunosorbent assay using multimers of the 16th non‐collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Experimental dermatology. 2007 Sep;16(9):770-7.
Ishii K, Amagai M, Hall RP, Hashimoto T, Takayanagi A, Gamou S, Shimizu N, Nishikawa T. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. Journal of Immunology (Baltimore, Md.: 1950). 1997 Aug 15;159(4):2010-7.
Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, Bystryn JC, Cianchini G, Diaz L, Fivenson D, Hall R. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. Journal of the American Academy of Dermatology. 2008 Jun 1;58(6):1043-6.
Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, Vaillant L, D'Incan M, Plantin P, Bedane C, Young P. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. New England Journal of Medicine. 2002 Jan 31;346(5):321-7.
Martin LK, Werth VP, Villaneuva EV, Murrell DF. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. Journal of the American Academy of Dermatology. 2011 May 1;64(5):903-8.
Beissert S, Werfel T, Frieling U, Böhm M, Sticherling M, Stadler R, Zillikens D, Rzany B, Hunzelmann N, Meurer M, Gollnick H. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Archives of dermatology. 2007 Dec 1;143(12):1536-42.
Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. Journal of investigative dermatology. 2010 Aug 1;130(8):2041-8.
Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, Chalmers JR, Childs M, Walton S, Harman K, Chapman A. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. The Lancet. 2017 Apr 22;389(10079):1630-8.
Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. The Lancet. 2017 May 20;389(10083):2031-40.
Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Archives of dermatology. 2003 Aug 1;139(8):1051-9
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
